Table 3 Rash Management
Analysis Set (N = 68) | SPARTAN | TITAN | PCR1008 | Total |
|---|---|---|---|---|
Number of patients in safety analysis set, n | 34 | 28 | 6 | 68 |
Rash, n (%) | 19 (55.88) | 14 (50.00) | 2 (33.33) | 35 (51.47) |
Patients who received supportive care for rash, n (%) | ||||
Oral antihistamine | 11 (57.89) | 6 (42.86) | 1 (50.00) | 18 (51.43) |
Systemic corticosteroid | 0 (0.00) | 3 (21.43) | 0 (0.00) | 3 (8.57) |
Topical corticosteroid | 13 (68.42) | 13 (92.86) | 1 (50.00) | 27 (77.14) |
Drug interruption | 11 (57.89) | 6 (42.86) | 1 (50.00) | 18 (51.43) |
Dose reduction | 4 (21.05) | 3 (21.43) | 0 (0.00) | 7 (20.00) |
Drug discontinuation | 3 (15.79) | 2 (14.29) | 0 (0.00) | 5 (14.29) |
Other | 2 (10.53) | 1 (7.14) | 0 (0.00) | 3 (8.57) |